<DOC>
	<DOCNO>NCT01401166</DOCNO>
	<brief_summary>This randomize , open-label , crossover study evaluate participant ' preference healthcare professional ( HCP ) satisfaction SC versus IV Herceptin administration HER2-positive early breast cancer . Participants randomize receive either SC Herceptin IV Herceptin every 3 week Cycles 1 4 , follow crossover treatment administration Cycles 5 8 . For 10 additional cycle ( total 18 cycle ) , participant receive IV SC Herceptin every 3 week .</brief_summary>
	<brief_title>Participant Preference Subcutaneous ( SC ) Versus Intravenous ( IV ) Herceptin ( Trastuzumab ) Human Epidermal Growth Factor Receptor ( HER ) 2-Positive Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm HER2positive primary breast cancer No evidence residual , locally recurrent , metastatic disease completion surgery chemotherapy ( neoadjuvant adjuvant ) Completed neoadjuvant chemotherapy prior entry , receive At least 8 remain cycle total 18 plan 3week cycle , receive IV Herceptin Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 History malignancy , except ductal carcinoma situ breast , curatively treat carcinoma situ cervix , basal cell carcinoma , curatively treated malignancy participant diseasefree least 5 year Inadequate bone marrow function Impaired liver function Inadequate renal function Serious cardiovascular disease Human immunodeficiency virus hepatitis B C infection Prior maximum cumulative dose doxorubicin great ( &gt; ) 360 milligram per metersquared ( mg/m^2 ) epirubicin &gt; 720 mg/m^2 equivalent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>